Evaluating immune response to viruses in stem cell transplant patients
Evaluation of Cytomegalovirus and Epstein-Barr Virus Specific Immune Reformulation in Prophylaxis for Cytomegalovirus in Haploid Hematopoietic Stem Cell Transplantation
This study is testing how well the immune system fights off certain viruses in patients getting a specific type of stem cell transplant for blood disorders.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 60 (estimated) |
| Ages | 16 Years to 60 Years |
| Sex | All |
| Sponsor | The First Affiliated Hospital of Soochow University Academic / other |
| Locations | 1 site (Suzhou, Jiangsu) |
| Trial ID | NCT06554197 on ClinicalTrials.gov |
What this trial studies
This observational study aims to assess the immune reestablishment against cytomegalovirus (CMV) and Epstein-Barr virus (EBV) in patients undergoing haploidentical hematopoietic stem cell transplantation (haplo-HSCT). It is a prospective, open-label, single-arm study conducted at a single center. The focus is on patients diagnosed with hemopathy who are receiving prophylaxis for CMV during their treatment. The study will monitor the immune response specific to these viruses to better understand their management in transplant patients.
Who should consider this trial
Good fit: Ideal candidates are patients diagnosed with hemopathy who are indicated for haploidentical hematopoietic stem cell transplantation and require prophylaxis for cytomegalovirus.
Not a fit: Patients with conditions deemed unsuitable for the trial by investigators will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could improve the management of viral infections in patients undergoing stem cell transplantation.
How similar studies have performed: While this approach is focused on a specific patient population, similar studies evaluating immune responses in transplant settings have shown promising results.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. All patients were diagnosed with hemopathy. 2. All patients should have the indication of Haploidentical hematopoietic stem cell transplant and receive the prophylaxis for cytomegalovirus. 3. All patients should sign an informed consent document indicating that they understand the purpose of and procedures required for the study and be willing to participate in the study. Exclusion Criteria: Patients with any conditions not suitable for the trial (investigators' decision).
Where this trial is running
Suzhou, Jiangsu
- First Affiliated Hospital of Soochow University — Suzhou, Jiangsu, China (Recruiting)
Study contacts
- Study coordinator: Feng Chen, PhD
- Email: 13584861215@163.com
- Phone: 13584861215
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.